Hormone replacement therapy is associated with increased C-reactive protein in women with Type 2 diabetes in the Diabetes Heart Study

Diabetic Medicine

Volumn 23, Issue 7, 2006, Pages 763-767

  Bowden, D W ^a   Lohman, K ^a   Hsu, F C ^a   Langefeld, C D ^a   Carr, J J ^a   Lenchik, L ^a   Wagenknecht, L E ^a   Freedman, B I ^a   Herrington, D M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; Diabetes; Hormone replacement therapy; Inflammation; Women's health

Indexed keywords

C REACTIVE PROTEIN; ESTROGEN; HORMONE; PROGESTERONE;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; WOMEN'S HEALTH;

BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 33748519260     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01912.x     Document Type: Article

References (21)

1. Ross R, Agius L. The process of atherogenesis - cellular and molecular interaction: from experimental animal models to humans. Diabetologia 1992; 35: S34-40.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
3. Mendall MA, Strachan DP, Butland BK, Mendall MA, Ballam L. Morris J et al. C-reactive protein: relation to total mortality, cardiovascular mortality, and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584-1590.
4. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
5. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
6. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 2004; 50: 574-581.
7. Sattar N, Perera M, Small M, Lumsden MA. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type 2 diabetes. Lancet 1999; 354: 487-488.
8. Brussaard HE, Leuven JA, Krans HM, Kluft C. The effect of 17β-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus. Vascul Pharmacol 2002; 39: 141-147.
9. Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD. Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes. Diabet Med 2002; 19: 847-852.
10. Streja D, Cressey P, Rabkin SW. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complications 2003; 17: 120-127.
11. Fenkci S, Fenkci V, Yilmazer M, Serteser M, Koken T. Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in post-menopausal women with type 2 diabetes or hypertension. Hum Reprod 2003; 18: 866-870.
12. McKenzie J, Jaap AJ, Gallacher S, Kelly A, Crawford L, Greer IA et al. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clin Endocrinol 2003; 59: 682-689.
13. Stojanovic ND, Kwong P, Byrne DJ, Arnold A, Jagroop IA, Nair D et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in post-menopausal women with type 2 diabetes: a pilot study. Angiology 2003; 54: 391-399.
14. Zhang Y, Howard BV, Cowan LD, Welty TK, Schaefer CF, Wild RA et al. Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and non-diabetic American Indian women: the Strong Heart Study. J Women's Health 2004; 13: 155-163.
15. Bowden DW, Lange LA, Langefeld CD, Brosnihan KB, Freedman BI, Carr JJ et al. The relationship between C-reactive protein and subclinical cardiovascular disease in the Diabetes Heart Study. Am Heart J 2005; 150: 1032-1038.
16. Wagenknecht LE, Bowden DW, Carr JJ, Langefeld CD, Freedman BI, Rich SS. Familial aggregation of coronary artery calcium in families with Type 2 diabetes. Diabetes 2001; 50: 861-866.
17. Lange LA, Bowden DW, Langefeld CD, Wagenknecht LE, Carr JJ, Rich SS et al. Heritability of carotid artery intimal medial thickness in type 2 diabetes. Stroke 2002; 33: 1876-1881.
18. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130.
19. Snedecor GW, Cochran WG. Statistical Methods. Eighth Edn. Ames, IA: Iowa State University Press, 1989.
20. Silvestri A, Gebara O, Vitale C, Wajngarten M, Leonardo F, Ramires JA et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107: 3165-3169.
21. Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL et al. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study. Thromb Haemost 2005; 93: 1108-1116.